+

WO2005079840A3 - Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique - Google Patents

Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique Download PDF

Info

Publication number
WO2005079840A3
WO2005079840A3 PCT/EP2005/001711 EP2005001711W WO2005079840A3 WO 2005079840 A3 WO2005079840 A3 WO 2005079840A3 EP 2005001711 W EP2005001711 W EP 2005001711W WO 2005079840 A3 WO2005079840 A3 WO 2005079840A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
metabolic syndrome
preventing
secreted protein
protein products
Prior art date
Application number
PCT/EP2005/001711
Other languages
English (en)
Other versions
WO2005079840A2 (fr
Inventor
Daria Onichtchouk
Original Assignee
Develogen Ag
Daria Onichtchouk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Daria Onichtchouk filed Critical Develogen Ag
Priority to EP05701416A priority Critical patent/EP1730189A2/fr
Priority to US10/589,677 priority patent/US20070248579A1/en
Publication of WO2005079840A2 publication Critical patent/WO2005079840A2/fr
Publication of WO2005079840A3 publication Critical patent/WO2005079840A3/fr
Priority to US12/437,851 priority patent/US20090298771A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur l'utilisation: de protéines SF01-SF13 sécrétées; des polynucléotides codant pour elles; et de leurs effecteurs/modulateurs, pour le diagnostic, l'étude, la prévention et le traitement de maladies du pancréas (par exemple le diabète sucré), de l'obésité et/ou du syndrome métabolique, et la régénération de tissus tels que les tissus pancréatiques ou autres.
PCT/EP2005/001711 2004-02-20 2005-02-18 Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique WO2005079840A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05701416A EP1730189A2 (fr) 2004-02-20 2005-02-18 Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique
US10/589,677 US20070248579A1 (en) 2004-02-20 2005-02-18 Use of Secreted Protein Products for Preventing and Treating Pancreatic Diseases and/or Obesity and/or Metabolic Syndrome
US12/437,851 US20090298771A1 (en) 2004-02-20 2009-05-08 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003914 2004-02-20
EP04003914.1 2004-02-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/437,851 Division US20090298771A1 (en) 2004-02-20 2009-05-08 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Publications (2)

Publication Number Publication Date
WO2005079840A2 WO2005079840A2 (fr) 2005-09-01
WO2005079840A3 true WO2005079840A3 (fr) 2006-10-26

Family

ID=34878165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001711 WO2005079840A2 (fr) 2004-02-20 2005-02-18 Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique

Country Status (6)

Country Link
US (2) US20070248579A1 (fr)
EP (2) EP2096120B1 (fr)
AT (1) ATE549352T1 (fr)
DK (1) DK2096120T3 (fr)
ES (1) ES2384134T3 (fr)
WO (1) WO2005079840A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092214A1 (fr) * 2007-02-02 2008-08-07 Minomic International Limited Biomarqueurs pour le diabète
EP2797619A4 (fr) * 2011-12-30 2015-07-08 Joslin Diabetes Center Inc Compositions à base de glypican-4 et procédés destinés au traitement et au diagnostic d'une résistance à l'insuline
CN103113468B (zh) * 2013-01-17 2014-05-21 中国人民解放军军事医学科学院基础医学研究所 一种抗肿瘤蛋白质
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for preventing type 1 diabetes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000672A1 (fr) * 1999-06-29 2001-01-04 Millennium Pharmaceuticals, Inc. Proteines secretees et leurs utilisations
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
WO2003077939A1 (fr) * 2002-03-19 2003-09-25 Genset Sa Traitement de troubles du metabolisme par des agonistes et antagonistes d'un membre (fradj and/or cryptic) de la famille des recepteurs du tnf

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5886029A (en) * 1997-09-05 1999-03-23 Dhaliwal; Kirpal S. Method and composition for treatment of diabetes
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000672A1 (fr) * 1999-06-29 2001-01-04 Millennium Pharmaceuticals, Inc. Proteines secretees et leurs utilisations
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
WO2003077939A1 (fr) * 2002-03-19 2003-09-25 Genset Sa Traitement de troubles du metabolisme par des agonistes et antagonistes d'un membre (fradj and/or cryptic) de la famille des recepteurs du tnf

Also Published As

Publication number Publication date
ES2384134T3 (es) 2012-06-29
EP1730189A2 (fr) 2006-12-13
EP2096120A2 (fr) 2009-09-02
US20070248579A1 (en) 2007-10-25
EP2096120A3 (fr) 2009-12-02
US20090298771A1 (en) 2009-12-03
ATE549352T1 (de) 2012-03-15
DK2096120T3 (da) 2012-07-09
EP2096120B1 (fr) 2012-03-14
WO2005079840A2 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
WO2008080082A3 (fr) Procédés de modulation de set et utilisations associées
WO2003057134A8 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
WO2007009894A3 (fr) Nouveaux peptides utilises dans le traitement de l'obesite
WO2009051706A3 (fr) Composés peptidiques pour le traitement de l'obésité et de la résistance à l'insuline
WO2007106577A3 (fr) Utilisation de la gelsoline pour traiter la sclérose en plaques et pour diagnostiquer des maladies neurologiques
WO2008054561A3 (fr) Protéines, acides nucléiques encodant celles-ci et leurs procédés d'utilisation associés
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
WO2007146425A3 (fr) Composés et procédés destinés au traitement prophylactique d'une anémie induite par une chimiothérapie
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO2006128041A3 (fr) Compositions et procedes destines a traiter ou a prevenir un neoplasme chimiomoresistant
WO2008088524A3 (fr) Protéine r-spondine 1 à carence en domaines de thrombospondine utilisee en tant que facteur de prolifération épithéliale du tractus gastro-intestinal
WO2006116609A8 (fr) Procedes permettant de traiter les maladies des neurones moteurs peripheriques et compositions associees
WO2005079840A3 (fr) Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2006048452A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2003102185A3 (fr) Procedes et compositions pour traiter une neoplasie associee aux molecules d'acides nucleiques de a1 et a2 de hnrnp
WO2005053728A3 (fr) Protéines associées à l'adiposité et leur utilisation à des fins thérapeutiques et diagnostiques
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2007097922A3 (fr) Système de détoxication du sang à base de récepteur
WO2006017171A3 (fr) Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance
WO2007139970A3 (fr) Gène men1 pour le diagnostic et le traitement du diabète
WO2005005471A3 (fr) Utilisation de produits des proteines dg153 ou dg177 secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite et/ou du syndrome metabolique
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10589677

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005701416

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005701416

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10589677

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载